Vol. 2 No. 1 (2025)

Review Articles

The Latest Research Progress of IER3 in Clinical Significance and Mechanisms: Hepatocellular Carcinoma and Other Malignant Tumors

Published 2025-05-31

  • Wenbing Li
    • ,
  • Xinlong Zhang
    • ,
  • Yanting Yang
    • ,
  • Zenghua Zhou
    • ,
  • Zhenbo Huang
    • ,
  • Hui Li

Wenbing Li
Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China

Xinlong Zhang
Department of Cardiovascular medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Yanting Yang
Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China

Zenghua Zhou
Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China

Zhenbo Huang
Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China

Hui Li
Department of Neurosurgery, Guangxi Medical University Cancer Hospital, Nanning, China 


Abstract

Malignant tumor is one of the diseases threatening human health, and liver cancer is the most common. Hepatocellular carcinoma (HCC) is the most common clinicopathological subtype. Immediate early response 3 (IER3) plays a regulatory role in a variety of malignant tumors. This article reviews the latest research progress on the clinical significance and mechanism of IER3 in HCC and a variety of malignant tumors.

Keywords

Hepatocellular carcinoma, Immediate early response 3, Clinical significance, Mechanism

PDF

References

  1. SIEGEL R L, KRATZER T B, GIAQUINTO A N, et al. Cancer statistics, 2025 [J]. CA: a cancer journal for clinicians, 2025, 75(1): 10-45.
  2. JAYABALAN D, DHAKAL S, RAGURAGAVAN A, et al. Hepatocellular Carcinoma and Health-Related Quality of Life: A Systematic Review of Outcomes From Systemic Therapies [J]. International journal of hepatology, 2025, 2025: 1083642.
  3. GUO X, SONG J, ZHU L, et al. Multiparametric MRI-based radiomics and clinical nomogram predicts the recurrence of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization [J]. BMC cancer, 2025, 25(1): 683.
  4. UYSAL M, WEHRLE C J, SATISH S, et al. Histotripsy of Liver Tumors: Patient Selection, Ethical Discussions, and How We Do It [J]. Cancers, 2025, 17(7).
  5. KANDURI M, SUBHASH S, PUTINO R, et al. IER3: exploring its dual function as an oncogene and tumor suppressor [J]. Cancer gene therapy, 2025, 32(4): 450-63.
  6. WANG Q, ZHANG C, PANG Y, et al. Comprehensive analysis of bulk, single-cell RNA sequencing, and spatial transcriptomics revealed IER3 for predicting malignant progression and immunotherapy efficacy in glioma [J]. Cancer cell international, 2024, 24(1): 332.
  7. CHEN Y, HUANG Z, CHEN S, et al. Immediate early response 3 gene promotes aggressive progression and autophagy of AML by negatively regulating AKT/mTOR [J]. Translational oncology, 2023, 35: 101711.
  8. DALALI S, KAVIANI F, MAHDEVAR M, et al. Analysing glycolysis-related genes reveals the prognostic and diagnostic relevance of IER3 and AGRN in colorectal cancer [J]. Genes & genomics, 2025.
  9. HE F Y, CHEN G, HE R Q, et al. Expression of IER3 in hepatocellular carcinoma: clinicopathology, prognosis, and potential regulatory pathways [J]. PeerJ, 2022, 10: e12944.
  10. ZHOU W, ZHANG S, CAI Z, et al. A glycolysis-related gene pairs signature predicts prognosis in patients with hepatocellular carcinoma [J]. PeerJ, 2020, 8: e9944.
  11. TRAN D D H, KOCH A, ALLISTER A, et al. Treatment with MAPKAP2 (MK2) inhibitor and DNA methylation inhibitor, 5-aza dC, synergistically triggers apoptosis in hepatocellular carcinoma (HCC) via tristetraprolin (TTP) [J]. Cellular signalling, 2016, 28(12): 1872-80.
  12. LIU Z, WANG X M, JIA T F, et al. Expression of IER3 in primary hepatocarcinoma: correlation with clinicopathological parameters [J]. Asian Pacific journal of cancer prevention: APJCP, 2015, 16(2): 679-82.
  13. LING CHU J Z, RUOYU MENG, QUAN ZHUANG. Evaluating the role of IER3+ macrophages in the prognosis of liver fibrosis by bulk and single-cell transcriptional analyses [J]. iLIVER, 2024, 3(4): 100132.
  14. KUANG T, ZHANG L, CHAI D, et al. Construction of a T-cell exhaustion-related gene signature for predicting prognosis and immune response in hepatocellular carcinoma [J]. Aging, 2023, 15(12): 5751-74.
  15. XIAOHUI C, XIN L I, DEHUA W U. [E26 transformation-specific variant 4 promotes sorafenib and cisplatin resistance in hepatocellular carcinoma cells in vitro] [J]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2019, 39(8): 875-82.
  16. LIU S, QIU J, HE G, et al. TRAIL promotes hepatocellular carcinoma apoptosis and inhibits proliferation and migration via interacting with IER3 [J]. Cancer cell international, 2021, 21(1): 63.
  17. EMMA M R, IOVANNA J L, BACHVAROV D, et al. NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance [J]. Cell death & disease, 2016, 7(6): e2269.
  18. KWON S M, KIM D S, WON N H, et al. Genomic copy number alterations with transcriptional deregulation at 6p identify an aggressive HCC phenotype [J]. Carcinogenesis, 2013, 34(7): 1543-50.
  19. WEST A C, TANG K, TYE H, et al. Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancer [J]. Oncogene, 2017, 36(36): 5134-44.
  20. SASADA T, TAKEDATSU H, AZUMA K, et al. Immediate early response gene X-1, a stress-inducible antiapoptotic gene, encodes cytotoxic T-lymphocyte (CTL) epitopes capable of inducing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric cancer patients [J]. Cancer research, 2004, 64(8): 2882-8.
  21. TSUTSUMI C, OHUCHIDA K, KATAYAMA N, et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells contribute to the development of an immunosuppressive tumor microenvironment in gastric cancer [J]. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024, 27(2): 248-62.
  22. SASADA T, AZUMA K, HIRAI T, et al. Prognostic significance of the immediate early response gene X-1 (IEX-1) expression in pancreatic cancer [J]. Annals of surgical oncology, 2008, 15(2): 609-17.
  23. LI Y, DING Z, CHENG T, et al. Single-cell transcriptomics analysis reveals dynamic changes and prognostic signature in tumor microenvironment of PDAC [J]. Scientific reports, 2025, 15(1): 4025.
  24. GARCIA M N, GRASSO D, LOPEZ-MILLAN M B, et al. IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation [J]. The Journal of clinical investigation, 2014, 124(11): 4709-22.
  25. MOLEJON M I, IOVANNA J L. IER3 in pancreatic carcinogenesis [J]. Oncotarget, 2015, 6(18): 15712-3.
  26. LEE S, BANG S, SONG K, et al. Differential expression in normal-adenoma-carcinoma sequence suggests complex molecular carcinogenesis in colon [J]. Oncology reports, 2006, 16(4): 747-54.
  27. SEBENS MüERKöSTER S, RAUSCH A V, ISBERNER A, et al. The apoptosis-inducing effect of gastrin on colorectal cancer cells relates to an increased IEX-1 expression mediating NF-kappa B inhibition [J]. Oncogene, 2008, 27(8): 1122-34.
  28. NAMBIAR P R, NAKANISHI M, GUPTA R, et al. Genetic signatures of high- and low-risk aberrant crypt foci in a mouse model of sporadic colon cancer [J]. Cancer research, 2004, 64(18): 6394-401.
  29. YE J, ZHANG Y, CAI Z, et al. Increased expression of immediate early response gene 3 protein promotes aggressive progression and predicts poor prognosis in human bladder cancer [J]. BMC urology, 2018, 18(1): 82.
  30. HAN L, GENG L, LIU X, et al. Clinical significance of IEX-1 expression in ovarian carcinoma [J]. Ultrastructural pathology, 2011, 35(6): 260-6.
  31. LEE Y H, KIM J H, ZHOU H, et al. Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma [J]. Journal of molecular medicine (Berlin, Germany), 2012, 90(4): 427-34.
  32. LI Y, TAN C, LIU L, et al. Significance of blood and salivary IEX-1 expression in diagnosis of epithelial ovarian carcinoma [J]. The journal of obstetrics and gynaecology research, 2018, 44(4): 764-71.
  33. JORDAN K R, SIKORA M J, SLANSKY J E, et al. The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval [J]. Clinical cancer research: an official journal of the American Association for Cancer Research, 2020, 26(23): 6362-73.
  34. YANG J, XIANG C, LIU J. Clinical significance of combining salivary mRNAs and carcinoembryonic antigen for ovarian cancer detection [J]. Scandinavian journal of clinical and laboratory investigation, 2021, 81(1): 39-45.
  35. JIN H, SUH D S, KIM T H, et al. IER3 is a crucial mediator of TAp73β-induced apoptosis in cervical cancer and confers etoposide sensitivity [J]. Scientific reports, 2015, 5: 8367.
  36. JIN H, LEE K, KIM Y H, et al. Scaffold protein FHL2 facilitates MDM2-mediated degradation of IER3 to regulate proliferation of cervical cancer cells [J]. Oncogene, 2016, 35(39): 5106-18.
  37. ITO T, OZAKI S, CHANASONG R, et al. Activation of ERK/IER3/PP2A-B56γ-positive feedback loop in lung adenocarcinoma by allelic deletion of B56γ gene [J]. Oncology reports, 2016, 35(5): 2635-42.
  38. YAMASHITA K, NAKASHIMA S, YOU F, et al. Overexpression of immediate early gene X-1 (IEX-1) enhances gamma-radiation-induced apoptosis of human glioma cell line, U87-MG [J]. Neuropathology: official journal of the Japanese Society of Neuropathology, 2009, 29(1): 20-4.
  39. LOCATELLI S L, CAREDDU G, STIRPARO G G, et al. Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation [J]. Scientific reports, 2016, 6: 35745.
  40. XIAO F, DAI Y, HU Y, et al. Expression profile analysis identifies IER3 to predict overall survival and promote lymph node metastasis in tongue cancer [J]. Cancer cell international, 2019, 19: 307.